Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.33 |
| ▸ | CCNK | O75909 | 3/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CDK7 | P50613 | 3/20 | 0.32 |
| ▸ | CCNH | P51946 | 3/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.32 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211884 | 0.93 | CCNT1 (0.40) | LIPGTP53CCNT1 | |
| SCHEMBL4342593 | 0.92 | CCNA2 (0.33) | SIGMAR1CCNKCCNA2CDK2CDK7 | |
| SCHEMBL212841 | 0.91 | DYRK1A (0.35) | DYRK1AGSK3BLIPGWNT1 | |
| SCHEMBL4346889 | 0.91 | ABL1 (0.31) | DYRK1AGSK3BWNT1 | |
| SCHEMBL4340751 | 0.89 | SIGMAR1 (0.33) | SIGMAR1CCNKCCNA2CDK2CDK7 | |
| SCHEMBL2839468 | 0.87 | DYRK1A (0.32) | DYRK1AGSK3BLIPG | |
| SCHEMBL209633 | 0.87 | ABL1 (0.34) | — | |
| SCHEMBL4346941 | 0.87 | ITGB3 (0.31) | — | |
| SCHEMBL211211 | 0.85 | CCNT1 (0.38) | CCNT1 | |
| SCHEMBL212238 | 0.84 | P2RX4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | SIGMAR1 1653/4885CCNK 2753/4885CCNA2 2182/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | SIGMAR1 1653/4885CCNK 2753/4885CCNA2 2182/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | SIGMAR1 1653/4885CCNK 2753/4885CCNA2 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.